Lucid Group Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Lucid Group Inc trades at $3.8 (market cap $1.51B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| LCID | SLS | |
|---|---|---|
Market Cap | $1.51B | $2.27B |
Volume | 12,333,745 | 4,179,659 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $15.46 |
52-Week Low | $3.82 | $1.39 |
Typical Hold Time | 45 Days | — |
Enterprise Value | $4.40B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.79, down 2.57% on the day, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and faces fundamental challenges including significant losses, negative profit margins, and cash burn. Recent news highlights management's focus on cost savings and strategic partnerships while delaying key product launches like the Cosmos SUV.
The outlook remains challenging with persistent losses and high cash burn requiring additional financing. Analyst consensus is cautious with only 13% buy ratings and a $7.60 price target representing potential upside. Key risks include execution delays, competitive pressure, and potential dilution from future capital raises.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →